{"pmid":32243894,"title":"COVID-19 Infection in Cancer Patients: Early Observations and Unanswered Questions.","text":["COVID-19 Infection in Cancer Patients: Early Observations and Unanswered Questions.","Ann Oncol","Oh, William K","32243894"],"journal":"Ann Oncol","authors":["Oh, William K"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243894","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.annonc.2020.03.297","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663079112914239489,"score":7.6048946,"similar":[{"pmid":32208840,"title":"Clinical observation and management of COVID-19 patients.","text":["Clinical observation and management of COVID-19 patients.","Three leading infectious disease experts in China were invited to share their bedside observations in the management of COVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide frontline medical care. He depicts the clinical course of SARS-CoV-2 infection. Furthermore, he observes the significant abnormality of coagulation function and proposes that the early intravenous immunoglobulin and low molecular weight heparin anticoagulation therapy are very important. Professor Hongzhou Lu, a leader in China to try various anti-viral drugs, expresses concern on the quality of the ongoing clinical trials as most trials are small in scale and repetitive in nature, and emphasizes the importance of the quick publication of clinical trial results. Regarding the traditional Chinese medicine, Professor Lu suggests to develop a creative evaluation system because of the complicated chemical compositions. Professor Wenhong Zhang is responsible for Shanghai's overall clinical management of the COVID-19 cases. He introduces the team approach to manage COVID-19 patients. For severe or critically ill patients, in addition to the respiratory supportive treatment, timely multiorgan evaluation and treatment is very crucial. The medical decisions and interventions are carefully tailored to the unique characteristics of each patient.","Emerg Microbes Infect","Li, Taisheng","Lu, Hongzhou","Zhang, Wenhong","32208840"],"abstract":["Three leading infectious disease experts in China were invited to share their bedside observations in the management of COVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide frontline medical care. He depicts the clinical course of SARS-CoV-2 infection. Furthermore, he observes the significant abnormality of coagulation function and proposes that the early intravenous immunoglobulin and low molecular weight heparin anticoagulation therapy are very important. Professor Hongzhou Lu, a leader in China to try various anti-viral drugs, expresses concern on the quality of the ongoing clinical trials as most trials are small in scale and repetitive in nature, and emphasizes the importance of the quick publication of clinical trial results. Regarding the traditional Chinese medicine, Professor Lu suggests to develop a creative evaluation system because of the complicated chemical compositions. Professor Wenhong Zhang is responsible for Shanghai's overall clinical management of the COVID-19 cases. He introduces the team approach to manage COVID-19 patients. For severe or critically ill patients, in addition to the respiratory supportive treatment, timely multiorgan evaluation and treatment is very crucial. The medical decisions and interventions are carefully tailored to the unique characteristics of each patient."],"journal":"Emerg Microbes Infect","authors":["Li, Taisheng","Lu, Hongzhou","Zhang, Wenhong"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32208840","week":"202013|Mar 23 - Mar 29","doi":"10.1080/22221751.2020.1741327","keywords":["Clinical management","SARS","SARS-CoV-2","antiviral drugs","coronavirus"],"source":"PubMed","locations":["Chinese","Shanghai","China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1662444220160409600,"score":43.063957},{"pmid":32188753,"pmcid":"PMC7082143","title":"COVID-19: Knowns, Unknowns, and Questions.","text":["COVID-19: Knowns, Unknowns, and Questions.","The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the Hubei province in China in late 2019 demonstrates the epidemic potential of coronaviruses. The rapid spread of this virus across the world in only 2 months highlights the transmissibility of this family of viruses and the significant morbidity and mortality that they can cause. We highlight the current state of knowledge of coronavirus biology while answering questions concerning the current outbreak of SARS-CoV-2.","mSphere","Weston, Stuart","Frieman, Matthew B","32188753"],"abstract":["The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the Hubei province in China in late 2019 demonstrates the epidemic potential of coronaviruses. The rapid spread of this virus across the world in only 2 months highlights the transmissibility of this family of viruses and the significant morbidity and mortality that they can cause. We highlight the current state of knowledge of coronavirus biology while answering questions concerning the current outbreak of SARS-CoV-2."],"journal":"mSphere","authors":["Weston, Stuart","Frieman, Matthew B"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32188753","week":"202012|Mar 16 - Mar 22","doi":"10.1128/mSphere.00203-20","keywords":["*COVID-19","*SARS","*SARS-CoV-2","*coronavirus"],"source":"PubMed","locations":["China","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment","Transmission"],"weight":1,"_version_":1663095625914253312,"score":40.052074}]}